Evaluation of the Beneficial Effects of a GABA-based Product Containing on Post-inflammatory Irritable Bowel Syndrome: a Preclinical Study

Overview

Journal Front Pharmacol

Date 2024 Oct 7

PMID 39372212

Authors

Elena Lucarini

Laura Benvenuti

Clelia Di Salvo

Vanessa DAntongiovanni

Carolina Pellegrini

Giulia Valdiserra

Clara Ciampi

Luca Antonioli

Christian Lambiase

Lorenzo Cancelli

Antonio Grosso

Lorenzo Di Cesare Mannelli

Massimo Bellini

Carla Ghelardini

Matteo Fornai

Affiliations

Soon will be listed here.

Abstract

Introduction: Visceral pain represents the most common digestive issue, frequently resulting from long-term inflammation, such as inflammatory bowel diseases. The lack of effective drugs prompted search of new therapeutic approaches. In this regard, gamma-aminobutyric acid (GABA) and (Mo) appear as excellent candidates as they were recognized to have several positive effects on the digestive system. The aim of this research was to evaluate the effects of a compound containing GABA and Mo (GABA-Mo 5:1) in inflammation-induced intestinal damage and visceral pain.

Methods: Colitis was induced in rats by intrarectal 2,4-dinitrobenzenesulfonic acid (DNBS) administration. DNBS-treated animals received GABA-Mo (80 mg/kg BID), starting 3 days before DNBS administration, until 14 days after colitis induction (preventive protocol), or starting 7 days after DNBS until day 21 (curative protocol). Visceral pain was assessed by measuring the viscero-motor response (VMR) and the abdominal withdrawal reflex (AWR) to colorectal distension on day 7, 14 (both protocols) and 21 (curative protocol) after DNBS administration.

Results: In the preventive protocol, GABA-Mo reduced AWR at day 14 but had no effect on VMR. In the spinal cord, treatment with GABA-Mo significantly prevented microglia reactivity (Iba-1 positive cells). In the colon, the supplement significantly decreased malondialdehyde (MDA, index of oxidative stress) and IL-1β levels and counteracted the decreased expression of claudin-1. Moreover, GABA-Mo normalized the increased levels of plasma lipopolysaccharide binding protein (LBP, index of altered intestinal permeability). In the curative protocol, GABA-Mo significantly counteracted visceral hypersensitivity persistence in DNBS-treated animals (day 14 and 21). In the spinal cord, GABA-Mo significantly reduced GFAP positive cell density (astrocytes). Histological evaluations highlighted a mild but significant effect of GABA-Mo in promoting healing from DNBS-induced colon damage. Colonic MDA and myeloperoxidase (index of leukocyte infiltration) levels were reduced, while the decreased colonic claudin-1 expression was normalized. In addition, the increased levels of plasma LBP were normalized by GABA-Mo administration.

Discussion: In conclusion GABA-Mo, particularly in the curative protocol, was able to reduce visceral pain and intestinal inflammation, likely through a reinforcement of intestinal barrier integrity, thus representing a suitable approach for the management of abdominal pain, especially in the remission stages of colitis.

References

Gros M, Gros B, Mesonero J, Latorre E . Neurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management. J Clin Med. 2021; 10(15). PMC: 8347293. DOI: 10.3390/jcm10153429. View

Guginski G, Luiz A, Silva M, Massaro M, Martins D, Chaves J . Mechanisms involved in the antinociception caused by ethanolic extract obtained from the leaves of Melissa officinalis (lemon balm) in mice. Pharmacol Biochem Behav. 2009; 93(1):10-6. DOI: 10.1016/j.pbb.2009.03.014. View

Seguella L, Gulbransen B . Enteric glial biology, intercellular signalling and roles in gastrointestinal disease. Nat Rev Gastroenterol Hepatol. 2021; 18(8):571-587. PMC: 8324524. DOI: 10.1038/s41575-021-00423-7. View

Minderhoud I, Oldenburg B, Wismeijer J, van Berge Henegouwen G, Smout A . IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci. 2004; 49(3):469-74. DOI: 10.1023/b:ddas.0000020506.84248.f9. View

Ngo D, Vo T . An Updated Review on Pharmaceutical Properties of Gamma-Aminobutyric Acid. Molecules. 2019; 24(15). PMC: 6696076. DOI: 10.3390/molecules24152678. View

Docherty M, Jones 3rd R, Wallace M . Managing pain in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2012; 7(9):592-601. PMC: 3264972. View

Pokusaeva K, JOHNSON C, Luk B, Uribe G, Fu Y, Oezguen N . GABA-producing Bifidobacterium dentium modulates visceral sensitivity in the intestine. Neurogastroenterol Motil. 2016; 29(1). PMC: 5195897. DOI: 10.1111/nmo.12904. View

Zam W, Quispe C, Sharifi-Rad J, Lopez M, Schoebitz M, Martorell M . An Updated Review on The Properties of L.: Not Exclusively Anti-anxiety. Front Biosci (Schol Ed). 2022; 14(2):16. DOI: 10.31083/j.fbs1402016. View

Carlton S, Zhou S, Coggeshall R . Peripheral GABA(A) receptors: evidence for peripheral primary afferent depolarization. Neuroscience. 1999; 93(2):713-22. DOI: 10.1016/s0306-4522(99)00101-3. View

10.

Karimi-Abdolrezaee S, Billakanti R . Reactive astrogliosis after spinal cord injury-beneficial and detrimental effects. Mol Neurobiol. 2012; 46(2):251-64. DOI: 10.1007/s12035-012-8287-4. View

11.

Bellini M, Tonarelli S, Barracca F, Morganti R, Pancetti A, Bertani L . A Low-FODMAP Diet for Irritable Bowel Syndrome: Some Answers to the Doubts from a Long-Term Follow-Up. Nutrients. 2020; 12(8). PMC: 7468924. DOI: 10.3390/nu12082360. View

12.

Raghavendra V, Tanga F, DeLeo J . Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther. 2003; 306(2):624-30. DOI: 10.1124/jpet.103.052407. View

13.

Shaikh S, Sun N, Canakis A, Park W, Weber H . Irritable Bowel Syndrome and the Gut Microbiome: A Comprehensive Review. J Clin Med. 2023; 12(7). PMC: 10095554. DOI: 10.3390/jcm12072558. View

14.

McGrath J, Lilley E . Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol. 2015; 172(13):3189-93. PMC: 4500358. DOI: 10.1111/bph.12955. View

15.

Giamberardino M, Costantini R, Affaitati G, Fabrizio A, Lapenna D, Tafuri E . Viscero-visceral hyperalgesia: characterization in different clinical models. Pain. 2010; 151(2):307-322. DOI: 10.1016/j.pain.2010.06.023. View

16.

Lucarini E, Seguella L, Vincenzi M, Parisio C, Micheli L, Toti A . Role of Enteric Glia as Bridging Element between Gut Inflammation and Visceral Pain Consolidation during Acute Colitis in Rats. Biomedicines. 2021; 9(11). PMC: 8616000. DOI: 10.3390/biomedicines9111671. View

17.

Li T, Chen X, Zhang C, Zhang Y, Yao W . An update on reactive astrocytes in chronic pain. J Neuroinflammation. 2019; 16(1):140. PMC: 6615111. DOI: 10.1186/s12974-019-1524-2. View

18.

Sokovic Bajic S, Djokic J, Dinic M, Veljovic K, Golic N, Mihajlovic S . GABA-Producing Natural Dairy Isolate From Artisanal Zlatar Cheese Attenuates Gut Inflammation and Strengthens Gut Epithelial Barrier . Front Microbiol. 2019; 10:527. PMC: 6431637. DOI: 10.3389/fmicb.2019.00527. View

19.

Awad R, Levac D, Cybulska P, Merali Z, Trudeau V, Arnason J . Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Can J Physiol Pharmacol. 2007; 85(9):933-42. DOI: 10.1139/Y07-083. View

20.

Hyland N, Cryan J . A Gut Feeling about GABA: Focus on GABA(B) Receptors. Front Pharmacol. 2011; 1:124. PMC: 3153004. DOI: 10.3389/fphar.2010.00124. View